Breaking News

Shilpa Biologicals Opens Manufacturing Site for Fully Integrated ADC Development

The new bioconjugation site completes the CDMO’s capabilities across payload, linker, and Mab, with onboarding set to start in September.

By: Rachel Klemovitch

Assistant Editor

Shilpa Biologicals, a full-service CDMO, opened a dedicated bioconjugation suite at its Dharwad, India site. The suite is currently undergoing validation and is expected to begin onboarding client programs by September 2025. The new multi-client bioconjugation suite is built to support the manufacture of ADCs and other advanced bioconjugates. It includes 200L single-use bioconjugation reactors and a lyophilization capacity of up to 65 kg.  Complementary development laboratories will provid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters